Crescita Therapeutics (TSX:CTX) Total Operating Expense: C$13.17 Mil (TTM As of Mar. 2026)


TSX:CTX Crescita Therapeutics Inc TSX:CTX
20 GF Score
Price C$0.79
GF Value C$0.68
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Crescita Therapeutics Total Operating Expense?

Crescita Therapeutics TSX:CTX 20 Total Operating Expense is C$13.17 Mil as of Mar. 2026. GuruFocus rates TSX:CTX with a GF Score™ of 20/100 and a GF Value™ of C$0.68 (Modestly Overvalued). The stock has 5 warning signs investors should review.

Crescita Therapeutics's Total Operating Expense for the three months ended in Mar. 2026 was C$3.85 Mil. Crescita Therapeutics's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was C$13.17 Mil.

Crescita Therapeutics Total Operating Expense Related Terms

Crescita Therapeutics Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Crescita Therapeutics's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Crescita Therapeutics Total Operating Expense Chart

Crescita Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.73 12.65 12.32 12.21 12.13

Crescita Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.63 3.24 3.02 3.06 3.85
TSX:CTX
20GF Score
Crescita Therapeutics Inc TSX:CTX
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Crescita Therapeutics Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$13.17 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of C$13.17 Mil mean?
Crescita Therapeutics (TSX:CTX) has a Total Operating Expense of C$13.17 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Crescita Therapeutics and its competitors.
Is Crescita Therapeutics' Total Operating Expense too high?
Crescita Therapeutics' current Total Operating Expense is C$13.17 Mil. Overall, Crescita Therapeutics has a GF Score™ of 20/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Crescita Therapeutics' Total Operating Expense compare to ZTS?
Crescita Therapeutics' Total Operating Expense of C$13.17 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Drug Manufacturers company?
A good Total Operating Expense depends on the Drug Manufacturers industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Crescita Therapeutics and its competitors. Crescita Therapeutics's current Total Operating Expense is C$13.17 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Crescita Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Crescita Therapeutics (TSX:CTX) is currently considered Modestly Overvalued. The stock's GF Value™ is C$0.68, compared to a current price of C$0.79 — trading 16.2% above its estimated fair value. The current Total Operating Expense is C$13.17 Mil. Crescita Therapeutics' overall GF Score™ is 20/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Crescita Therapeutics (TSX:CTX), the current Total Operating Expense is C$13.17 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Crescita Therapeutics (TSX:CTX) Overvalued in 2026?

Based on GuruFocus' analysis, Crescita Therapeutics stock appears to be overvalued. The current stock price of C$0.79 is trading 16.2% above its estimated GF Value™ of C$0.68. GuruFocus considers Crescita Therapeutics to be Modestly Overvalued.

Key valuation signals for TSX:CTX:

  • Total Operating Expense: C$13.17 Mil
  • GF Value™: C$0.68 vs. price of C$0.79 (16.2% above fair value)
  • GF Score™: 20/100 with 5 warning signs

No single metric tells the full story. See the TSX:CTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Crescita Therapeutics Business Description

Address 2805, Place Louis-R-Renaud, Laval, QC, CAN, H7V 0A3
Crescita Therapeutics Inc is a commercial dermatology company with in-house research & development and manufacturing capabilities. The company offers a portfolio of non-prescription skincare products and early to commercial-stage prescription drug products and owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active ingredients into or through the skin. The company has three reportable segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. The firm generates its revenue from Commercial Skincare Product Sales in Canada followed by USA and Rest of the world.
20GF Score

Get the complete analysis for TSX:CTX

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$0.79
Price
C$0.68
GF Value